The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis

Background. Recently, radiotherapy has been used in the treatment of hepatocellular carcinoma (HCC). However, there is no study analyzing the efficacy of radiotherapy in cases of advanced HCC. The objective of this investigation was to determine the efficacy of radiotherapy in patients with HCC invading distant organs. Methods. The data of 2342 patients diagnosed between 2010 and 2015 with HCC invading distant organs were extracted from the SEER database. Propensity score matching (PSM) was used to reduce selection bias. Results. Before PSM, the median overall survival (mOS) and median cancer-specific survival (mCSS) in the radiotherapy group (mOS. 5 months, 95% CI: 4.5-5.5; mCSS. 5 months, 95% CI: 4.4-5.6) were longer than those in the nonradiotherapy group (mOS. 3 months, 95% CI: 2.8-3.2; mCSS. 3 months, 95% CI: 2.8-3.2; both P < 0.001). After PSM, mOS in the radiotherapy group (5 months, 95% CI: 4.5-5.5) was longer than that in the nonradiotherapy group (3 months, 95% CI: 2.6-3.4; P < 0.001), and the mCSS in the radiotherapy group (5 months, 95% CI: 4.4-5.6) was longer than that in the nonradiotherapy group (3 months, 95% CI: 2.6-3.4; P < 0.001). Before PSM, the multivariate analysis showed that all-cause and cancer-specific mortality rates were higher in the nonradiotherapy group than in the radiotherapy group. The adjusted Cox regression analysis for subgroups showed that, in the nonradiotherapy group, patients with bone metastases and multiorgan metastases had a worse survival than those in the radiotherapy group. Conclusion. HCC patients with metastases to distant organs obtain survival benefit from radiotherapy, particularly patients with bone metastases and multiorgan metastases.

Automated summary

This study analyzed the efficacy of radiotherapy in patients with hepatocellular carcinoma invading distant organs. The results showed that HCC patients with metastases to distant organs benefited from radiotherapy, especially those with bone metastases and multiorgan metastases.